Stability of Drugs and Dosage Forms

Sumie Yoshioka
National Institute of Health Sciences
Tokyo, Japan

and

Valentino J. Stella
The University of Kansas
Lawrence, Kansas

Kluwer Academic/Plenum Publishers
New York, Boston, Dordrecht, London, Moscow
Contents

1. Introduction ................................................................. 1

2. Chemical Stability of Drug Substances ................................. 3
   2.1. Pathways of Chemical Degradation ................................. 4
       2.1.1. Hydrolysis .................................................... 5
           2.1.1.1. Esters .................................................. 5
           2.1.1.2. Amides ............................................... 10
           2.1.1.3. Barbiturates, Hydantoins, and Imides ............... 12
           2.1.1.4. Schiff Base and Other Reactions Involving
                       Carbon–Nitrogen Bond Cleavage ....................... 15
           2.1.1.5. Other Hydrolysis Reactions .......................... 17
       2.1.2. Dehydration ................................................... 18
       2.1.3. Isomerization and Racemization ............................. 18
       2.1.4. Decarboxylation and Elimination ............................ 22
       2.1.5. Oxidation .................................................... 24
       2.1.6. Photodegradation ............................................ 28
       2.1.7. Drug–Excipient and Drug–Drug Interactions ............... 29
           2.1.7.1. Reactions of Bisulfite, an Antioxidant ............... 30
           2.1.7.2. Reaction of Amines with Reducing Sugars ............ 30
           2.1.7.3. Transesterification Reactions ......................... 33
   2.2. Factors Affecting Chemical Stability ............................. 34
       2.2.1. Basic Kinetic Principles ................................... 34
       2.2.2. The Role of Molecular Structure ............................ 37
       2.2.3. Rate Equations and Kinetic Models .......................... 38
           2.2.3.1. Kinetic Models to Describe Drug Degradation
                       in Solution ............................................. 39
           2.2.3.2. Kinetic Models Describing Chemical Drug
                       Degradation in the Solid State ......................... 52
           2.2.3.3. Calculation of Rate Constants by Fitting to Kinetic
                       Models .................................................. 61
       2.2.4. Temperature ................................................... 61
           2.2.4.1. General Principles .................................... 61
2.2.4.2. Quantitation of the Temperature Dependency of Degradation Rate Constants ........................................ 62
2.2.4.3. Stability in Frozen Solutions .................................. 78
2.2.5. pH and pH–Rate Profiles ........................................ 80
  2.2.5.1. V-Type and U-Type pH–Rate Profiles ......................... 82
  2.2.5.2. pH–Rate Profiles with Inflection Points Due to the Presence of One or More Ionized Groups .................. 84
  2.2.5.3. Bell-Shaped pH–Rate Profiles Due to Ionization of Multiple Groups or Change in Rate-Determining Steps .......... 94
  2.2.5.4. Miscellaneous pH–Rate Profiles .............................. 96
2.2.6. Buffer, General Acid–Base, and Nucleophilic–Electrophilic Catalysis .................................................. 97
2.2.7. Ionic Strength (Primary Salt Effects) ............................ 99
2.2.8. Dielectric Constant of Solvents .................................. 102
2.2.9. Oxygen ............................................................. 104
2.2.10. Light .............................................................. 106
2.2.11. Crystalline State and Polymorphism in Solid Drugs ............ 107
2.2.12. Effect of Moisture and Humidity on Solid and Semisolid Drugs ...................................................... 108
2.2.13. Excipients ......................................................... 113
  2.2.13.1. Effect of the Amount of Moisture Present in Excipients .................................................. 113
  2.2.13.2. Effect of the Physical State of Water Molecules in Excipients ........................................ 115
  2.2.13.3. Effect of the Mobility of Water Molecules in Excipients on Drug Degradation .................. 117
  2.2.13.4. Other Properties of Excipients ............................. 120
2.2.14. Miscellaneous Factors ............................................ 124
2.3. Stabilization of Drug Substances against Chemical Degradation ................................................... 125
  2.3.1. Stabilization by Modification of Molecular Structure of Drug Substances ........................................ 125
  2.3.2. Stabilization by Complex Formation ............................ 126
  2.3.3. Stabilization by the Formation of Inclusion Complexes with Cyclodextrins ........................................ 128
  2.3.4. Stabilization by Incorporation into Liposomes, Micelles, or Emulsions ........................................ 133
  2.3.5. Addition of Stabilizers Such as Antioxidants and Stabilization through the Use of Packaging ................ 135

3. Physical Stability of Drug Substances ........................................ 139
  3.1. Physical Degradation ................................................ 139
    3.1.1. Crystallization of Amorphous Drugs ......................... 139
    3.1.2. Transitions in Crystalline States ............................ 141
    3.1.3. Formation and Growth of Crystals .......................... 141
    3.1.4. Vapor-Phase Transfers Including Sublimation ............... 143
3.1.5. Moisture Adsorption .......................... 143
3.2. Factors Affecting Physical Stability .......... 144
3.3. Kinetics of Solid-Phase Transitions ........... 145

4. Stability of Dosage Forms ...................... 151

4.1. Preformulation and Formulation Stability Studies . 151
   4.1.1. Methods for Detecting Chemical and Physical Degradation . 151
      4.1.1.1. Thermal Analysis .......................... 152
      4.1.1.2. Diffuse Reflectance Spectroscopy ............ 155
      4.1.1.3. Miscellaneous Methods ..................... 156
   4.1.2. Factorial Analysis .......................... 157
4.2. Functional Changes in Dosage Forms with Time .. 159
   4.2.1. Changes in Mechanical Strength ............... 159
   4.2.2. Changes in Drug Dissolution from Tablets and Capsules . 160
      4.2.2.1. Effect of Formulation on Changes in Dissolution . 160
      4.2.2.2. Changes in Drug Release from Coated Dosage Forms . 162
      4.2.2.3. Changes in Capsule Shells with Time and Storage Conditions .......... 163
      4.2.2.4. Prediction of Changes in Dissolution .......... 165
   4.2.3. Changes in Melting Time of Suppositories .... 167
   4.2.4. Changes in Drug Release Rate from Polymeric Matrix Dosage Forms, Including Microspheres . 168
   4.2.5. Drug Leakage from Liposomes ................ 170
   4.2.6. Aggregation in Emulsions .................... 172
   4.2.7. Moisture Adsorption ........................ 174
   4.2.8. Discoloration .............................. 175
4.3. Effect of Packaging on Stability of Drug Products . 175
   4.3.1. Moisture Penetration ........................ 175
   4.3.2. Adsorption onto and Absorption into Containers and Transfer of Container Components into Pharmaceuticals . 176
4.4. Estimation of the Shelf Life (Expiration Period) of Drug Products . 178
   4.4.1. Extrapolation from Real-Time Data .......... 179
   4.4.2. Shelf-Life Estimation from Temperature-Accelerated Studies . 180
      4.4.2.1. Experimental Design of Accelerated Testing .... 180
      4.4.2.2. Estimation of Shelf Life Using Accelerated-Test Data at a Single Level of Temperature .......... 182
   4.4.3. Estimation of Shelf Life under Temperature-Fluctuating Conditions .......... 184

5. Stability of Peptide and Protein Pharmaceuticals ............ 187

5.1. Degradation of Peptide and Protein Pharmaceuticals . 187
   5.1.1. Chemical Degradation ........................ 187
      5.1.1.1. Deamidation ............................ 188
      5.1.1.2. Isomerization and Racemization .......... 189
5.1.1.3. Hydrolysis ............................................. 190
5.1.1.4. Cross-Linking through Disulfide Bond Formation and Other Covalent Interactions .................. 190
5.1.1.5. Oxidation ............................................. 192
5.1.2. Physical Degradation ..................................... 193
5.1.3. Degradation in Peptide and Protein Formulations .................................................. 194
5.2. Factors Affecting the Degradation of Peptide and Protein Drugs ............................................... 194
5.2.1. Moisture Content and Molecular Mobility ................. 194
5.2.2. The Role of Excipients ................................... 196
5.3. Degradation Kinetics of Peptide and Protein Pharmaceuticals .................................................. 197
5.3.1. Quantitative Description of Peptide and Protein Degradation .................................................. 197
5.3.2. Temperature Dependence of the Degradation Rate of Peptide and Protein Drugs ...................... 199

6. Regulations ......................................................... 205
6.2. ICH Harmonised Tripartite Guideline for Photostability Testing of New Drug Substances and Products ........... 217
6.3. Major Concerns Raised by the EU, the United States, and Japan at the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use .......... 223
6.3.1. Storage Conditions for Stability Testing ................. 223
6.3.2. Photostability Testing .................................... 223
6.3.3. Bracketing and Matrixing .................................. 224

References .......................................................... 227
Index .................................................................... 263